SEQUENCE LISTING

<110> Anthrogenesis Corporation

<120> CHIMERIC ANTIGEN RECEPTORS

<130> 12827-401-228

<140>
<141>

<150> 61/740,113
<151> 2012-12-20

<150> 61/779,925
<151> 2013-03-13

<160> 11

<170> PatentIn version 3.5

<210> 1
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 1

Pro Glu Pro Cys Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala
1 5 10 15

Val Ser Ser Gly Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser
20 25 30

Leu Ser Lys Met
35

<210> 2
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 2

Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly
1 5 10 15

Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu
20 25

<210> 3
<211> 23
<212> PRT
<213> Artificial Sequence

<220>

<223> synthetic peptide - CTLA4 transmembrane domain

<400> 3

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr
1 5 10 15

Ser Phe Leu Leu Thr Ala Val
20

<210> 4
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 4

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr
1 5 10 15

Ser Phe Leu Leu Thr
20

<210> 5
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 5

Phe Leu Leu Trp Ile Leu Val Ala Val Ser Leu Gly Leu Phe Phe Tyr
1 5 10 15

Ser Phe Leu Val Ser Ala Val Ser Leu Ser
20 25

<210> 6
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - PD-1 transmembrane domain

<400> 6

Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu
1 5 10 15

Leu Val Trp Val Leu Ala Val Ile Cys Ser Arg Ala Ala
20 25

<210> 7
<211> 21

<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - PD-1 transmembrane domain

<400> 7

Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu Leu Val Trp
1 5 10 15

Val Leu Ala Val Ile
20

<210> 8
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - PD-1 transmembrane domain

<400> 8

Phe Gln Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu
1 5 10 15

Val Leu Leu Val Trp Val Leu Ala Val Ile
20 25

<210> 9
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 9

Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro
1 5 10 15

Ser Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser
20 25 30

Gly Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys
35 40 45

Met

<210> 10
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - CTLA4 transmembrane domain

<400> 10

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr
1 5 10 15

Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met
20 25

<210> 11
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic peptide - PD-1 transmembrane domain

<400> 11

Phe Gln Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu
1 5 10 15

Val Leu Leu Val Trp Val Leu Ala Val Ile Cys Ser Arg Ala Ala
20 25 30